Drugs / Orca-Q
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06900192 | Mar 2025 → Aug 2029 expected | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05322850 | Aug 2022 → Sep 2026 | acute lymphoblastic leukemia, acute undifferentiated leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, leukemia, myeloid, accelerated-phase +1 | University of Florida | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Orca-Q | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05322850 ↗ |
| Modality | Cell therapy | “allogeneic hematopoietic cell transplant using a centrally manufactured engineered donor graft (Orca-Q)” NCT05322850 ↗ |
| Route | Intravenous | “intravenously following myeloablative conditioning” NCT05322850 ↗ |